Core Viewpoint - Recently, the company announced a proposal to spin off its subsidiary, Mandi, for independent listing on the Hong Kong Stock Exchange [1] Group 1: Spin-off Details - The proposed spin-off is expected to be executed through a physical distribution of Mandi shares to shareholders based on their respective holdings in the company [1] - Mandi has submitted an application to the Hong Kong Stock Exchange for the approval of its listing, which includes a global offering of new shares [1] Group 2: Ownership Structure - As of the announcement date, Mandi is approximately 87.16% owned by the company, with other shareholders including Intai Management Limited (3.38%), Mandi Group Limited (2.80%), GLWecan Investment IV L.P. (4.00%), and Alibaba Health (Hong Kong) Technology Co., Ltd. (2.65%) [1]
三生制药：拟分拆蔓迪股份在香港联交所独立上市